Orphanet Journal of Rare Diseases · 16 July 2025
A father developed the gene therapy Melpida within 36 months of his son's diagnosis; the case draws four lessons for caregivers funding rare-disease drugs.
Deanna Portero, Qingyang Xu, Aaliya Hussain and Andrew W. Lo tell how Terry Pirovolakis developed Melpida, a gene therapy for his infant son Michael, within 36 months of the diagnosis, and analyse Elpida Therapeutics, the social purpose corporation he founded in May 2023 to repeat that success for other rare diseases. Melpida cost $4.5 million to develop and test, including $2 million for manufacturing; fundraising raised over $2.8 million and in-kind donations and discounts were worth about $3 million. Elpida plans to fund further therapies by reselling priority review vouchers, each worth about $100 million against $20-$35 million to bring a therapy to market, but the authors find its model not yet self-sustaining.